The present application provides a microsphere in which a main agent is uniformly dispersed in a polymer matrix, wherein an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less, and a variation coefficient of area ratios in four regions is 0.35 or less, wherein the area ratios in four regions are calculated by (s/A)×100 (%) wherein the four regions are prepared by preparing a cross section observation sample obtained by cutting the microsphere; observing the cross section observation sample with an electron microscope at a magnification capable of confirming the main agent in the microsphere or a higher magnification; and dividing the electron microscope observation image into four regions; and A is an area of a respective divided region, and s is a sum of cross section areas of the main agent included in the respective divided region. The microsphere of the present invention can appropriately control the initial release amount of the main agent and its release rate during a subsequent release period, and can continuously release the main agent for a predetermined period of time.

Embodiments of the invention relate generally to the use of formulations comprising DMSO and MSM to treat arthritis (such as osteoarthritis), pain, inflammation, and/or degeneration. DMSO and MSM formulations are administered orally and/or topically in several embodiments and provide effective treatment of both chronic and acute symptoms of arthritis (e.g., osteoarthritis), pain, inflammation, and/or degeneration. Solid forms of DMSO are provided in several embodiments.

Embodiments of the invention relate generally to the use of formulations comprising DMSO and MSM to treat arthritis (such as osteoarthritis), pain, inflammation, and/or degeneration. DMSO and MSM formulations are administered orally and/or topically in several embodiments and provide effective treatment of both chronic and acute symptoms of arthritis (e.g., osteoarthritis), pain, inflammation, and/or degeneration. Solid forms of DMSO are provided in several embodiments.

Embodiments of the invention relate generally to the use of formulations comprising DMSO and MSM to treat arthritis (such as osteoarthritis), pain, inflammation, and/or degeneration. DMSO and MSM formulations are administered orally and/or topically in several embodiments and provide effective treatment of both chronic and acute symptoms of arthritis (e.g., osteoarthritis), pain, inflammation, and/or degeneration. Solid forms of DMSO are provided in several embodiments.

This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).

The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.

The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.

A cannabinoid formulation and method for ocular or nasal delivery. The method of administration includes providing eye drops that comprise an aqueous solution of at least one water soluble cannabinoid, saline, and a vasodilator; and administering the eye drops topically to an eye of the subject. In an alternate method the cannabinoid formulation is a nasal spray delivered through the nose of a subject. Preferably, the vasodilator is 0.9% methylsulfonylmethane (MSM) in a MSM solution so that the MSM solution has a concentration of 5-15% in the overall formulation. Additionally, the at least one water soluble cannabinoid is encapsulated with a phospholipid liposome.

A cannabinoid formulation and method for ocular or nasal delivery. The method of administration includes providing eye drops that comprise an aqueous solution of at least one water soluble cannabinoid, saline, and a vasodilator; and administering the eye drops topically to an eye of the subject. In an alternate method the cannabinoid formulation is a nasal spray delivered through the nose of a subject. Preferably, the vasodilator is 0.9% methylsulfonylmethane (MSM) in a MSM solution so that the MSM solution has a concentration of 5-15% in the overall formulation. Additionally, the at least one water soluble cannabinoid is encapsulated with a phospholipid liposome.

The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.